The company heralds a pivotal win with its menin inhibitor, but investors want to see data.

Approval decisions await Ono and SpringWorks, while key data approach for Pfizer and Arvinas’s SERD.

Investors will hope for a JP Morgan buying spree, while readouts could come from Kura, Allogene and MacroGenics.

Menin, BTK and a Car-T skirmish featured over the ASH weekend.

Enzomenib might be the most promising agent so far, on a cross-trial basis.

The group presents data with bleximenib plus chemo, but looks behind Kura’s contender.

Party season approaches; but first, conferences.

Syndax scored the first menin approval, but Kura is first with a licensing deal.

Response rates in relapsed NPM1-mutant AML look slightly worse than before, but QTc prolongation could be the real worry.